Fig. 4

PD-1⁺ T cells expand ex vivo and provide anti-myeloma immunity when given as ACT. a Experimental design. At day 0, Rag-1-deficient recipient mice were inoculated with 10⁶ 5T33-GFP cells iv. Five days later, mice received ex vivo-expanded T cells as ACT. Some mice also received 125 μg anti-PD-L1 intraperitoneally (ip) at the indicated time points. Control mice received no treatment. b Survival curves of mice treated with ACT consisting of 3-4 × 10⁶ PD-1⁺ T cells at a CD4:CD8 ratio of 1:1 with or without 125 μg anti-PD-L1. Moribund mice were euthanized. Data are combined from 2 independent experiments, with n = 6–7 mice per experimental group. c Survival curves of mice given the following: (1) No treatment, (2) 3-4 × 10⁶ PD-1⁺ CD4⁺ and CD8⁺ T cells at a ratio of 1:1 [PD-1⁺ T cells group], (3) 3-4 × 10⁶ PD-1⁻ CD4⁺ and CD8⁺ T cells at a ratio of 1:1 [PD-1⁻ T cells group], (4) 1.5-2 × 10⁶ PD-1⁺ CD8⁺ T cells alone, or (5) 1.5-2 × 10⁶ PD-1⁺ CD4⁺ T cells alone. All mice, except the ‘no treatment’ group, received 125 μg anti-PD-L1 ip on days 7, 10, 14 and 17 after myeloma inoculation. The data are combined from 3 to 4 independent experiments, with n = 11–15 mice per experimental group.